AI Summary
Patients with advanced bladder cancer may benefit from a new combination treatment that includes immunotherapy. The FORT-2 clinical trial demonstrated that this treatment is safe and tolerable for patients with locally advanced or metastatic bladder cancer. This approach has the potential to expand the number of patients who can benefit from immunotherapy, which works by utilizing the patient's own immune system to combat cancer.
Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer. The results show potential to broaden the number of patients with bladder cancer who could benefit from immunotherapy, an approach that harnesses a patient’s own immune system to fight cancer.